Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation

• Published in: Respiratory Research 2010, Vol.11, p.126
• Main Authors: Wan, Wing-Yan Heidi, Morris, Abigail, Kinnear, Gillian, Pearce, William, Mok, Joanie, Wyss, Daniel, Stevenson, Christopher S
• Format: Report
• Language: English
• Subjects: Anti-inflammatory drugs; Dosage and administration; Drug therapy; Health aspects; Lung diseases, Obstructive; Risk factors; Smoking
• ISSN: 1465-9921
• DOI: 10.1186/1465-9921-11-126

Background Candidate compounds being developed to treat chronic obstructive pulmonary disease are typically assessed using either acute or chronic mouse smoking models; however, in both systems compounds have almost always been administered prophylactically. Our aim was to determine whether the prophylactic effects of reference anti-inflammatory compounds in acute mouse smoking models reflected their therapeutic effects in (more clinically relevant) chronic systems. Methods To do this, we started by examining the type of inflammatory cell infiltrate which occurred after acute (3 days) or chronic (12 weeks) cigarette smoke exposure (CSE) using female, C57BL/6 mice (n = 7-10). To compare the effects of anti-inflammatory compounds in these models, mice were exposed to either 3 days of CSE concomitant with compound dosing or 14 weeks of CSE with dosing beginning after week 12. Budesonide (1 mg kg.sup.-1.sup.; i.n., q.d.), roflumilast (3 mg kg.sup.-1.sup.; p.o., q.d.) and fluvastatin (2 mg kg.sup.-1.sup.; p.o., b.i.d.) were dosed 1 h before (and 5 h after for fluvastatin) CSE. These dose levels were selected because they have previously been shown to be efficacious in mouse models of lung inflammation. Bronchoalveolar lavage fluid (BALF) leukocyte number was the primary endpoint in both models as this is also a primary endpoint in early clinical studies. Results To start, we confirmed that the inflammatory phenotypes were different after acute (3 days) versus chronic (12 weeks) CSE. The inflammation in the acute systems was predominantly neutrophilic, while in the more chronic CSE systems BALF neutrophils (PMNs), macrophage and lymphocyte numbers were all increased (p [less than] 0.05). In the acute model, both roflumilast and fluvastatin reduced BALF PMNs (p [less than] 0.01) after 3 days of CSE, while budesonide had no effect on BALF PMNs. In the chronic model, therapeutically administered fluvastatin reduced the numbers of PMNs and macrophages in the BALF (p [less than or equal to] 0.05), while budesonide had no effect on PMN or macrophage numbers, but did reduce BALF lymphocytes (p [less than] 0.01). Roflumilast's inhibitory effects on inflammatory cell infiltrate were not statistically significant. Conclusions These results demonstrate that the acute, prophylactic systems can be used to identify compounds with therapeutic potential, but may not predict a compound's efficacy in chronic smoke exposure models.